Protein kinases are the molecular switches of the cell. They control growth, division, communication, and survival by ...

New research reveals that neurons release a little-understood extracellular kinase called VLK to strengthen synaptic ...

Cornell researchers have developed a powerful new biosensor that reveals, in unprecedented detail, how and where kinases – ...

Research is underway for an experimental treatment for patients with succinate dehydrogenase (SDH) deficient gastrointestinal ...

The nod brings Bayer face-to-face in the market with Boehringer Ingelheim and AstraZeneca, each of which has its own HER2 ...

In this video from the American Academy of Ophthalmology meeting, Esther M. Bowie, MD, discusses what is “new and exciting” in wet age-related macular degeneration.Tyrosine kinase inhibitors being ...

Kygevvi is expected to be commercially available in the US in the first quarter of 2026. The Food and Drug Administration (FDA) has approved Kygevvi ® for the treatment of thymidine kinase 2 ...

HYRNUO is a reversible kinase inhibitor of human epidermal growth factor receptor 2 (HER2). In vitro, HYRNUO inhibited the phosphorylation of HER2, downstream signaling in cancer cells with HER2 ...

A new active substance attacks a key protein in tumor cells, leading to complete degradation. In cell experiments, this ...

In patients naïve to HER2-targeted therapy, the objective response rate was 71% with a median duration of response of 9.2 months.